Novartis expanded commercialization agreement with Amgen for AMG 334 (erenumab)
Novartis announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on a 2015…
Read More...
Read More...